PRP Injections Show Promise for Improving the Aging Voice
A small study links PRP injections to improved voice function in older adults, but controlled trials are needed to confirm benefits.
Summary
Age-related voice changes can make everyday communication harder. In a small retrospective study, researchers evaluated injections of platelet-rich plasma, prepared from patients' own blood, for this condition. Thirty-six patients, averaging about 73 years old, received two or three injections into a vocal cord muscle; 35 completed the primary protocol. Average self-reported voice difficulty fell from 7.17 to 4.57 out of 10, and the time patients could sustain a sound increased from 11.47 to 13.31 seconds. Expert voice ratings and imaging of vocal cord vibration also improved, although standard sound measurements did not change significantly. These findings suggest a potential treatment for the aging voice, not proof of effectiveness. The study lacked a control group, and this summary relies on the abstract only, which provides limited safety and durability information.
Detailed Summary
Aging can weaken the voice, making conversation more difficult and affecting everyday communication. Presbyphonia is the term for these voice changes related to aging. A small study explored whether injections of concentrated platelets from a patient's own blood could improve voice function without surgery. The findings suggest potential benefits but do not establish effectiveness.
Researchers retrospectively reviewed 36 patients with an average age of approximately 73 years at one center. Patients received two or three injections of platelet-rich plasma into a vocal cord muscle during office visits. Thirty-five completed the primary protocol. Assessments included perceived voice difficulty, expert ratings, sustained vocalization time, sound measurements, and imaging of vocal cord vibration.
Patients' average voice handicap scores decreased from 7.17 to 4.57 on a scale from zero to 10. Expert ratings of voice quality also improved. The average time patients could sustain a sound increased from 11.47 to 13.31 seconds. Imaging showed improved vibration in 82.9% of patients, while standard acoustic measurements showed no statistically significant changes.
Better vocal cord vibration correlated with greater reported improvement, although this association does not prove how the injections worked. Initial symptom severity also predicted treatment response, but the abstract does not specify the direction. These results support further study of platelet-rich plasma as a possible option for older adults with persistent voice problems.
However, this uncontrolled retrospective study cannot separate treatment effects from placebo responses, natural fluctuations, or other care. Its small sample and single center limit generalizability. The abstract does not provide detailed adverse event data or clarify how long benefits lasted, despite describing treatment as safe and well tolerated. This summary is based on the abstract only. Patients should discuss persistent voice changes with a specialist rather than view these findings as proof that injections reverse aging or replace established voice care options.
Key Findings
- Average self-reported voice handicap decreased from 7.17 to 4.57 out of 10 after treatment.
- Maximum sustained vocalization increased from 11.47 to 13.31 seconds, a statistically significant improvement.
- Vocal cord vibration improved in 82.9% of patients and correlated with greater self-reported improvement.
- Expert voice ratings improved, but standard acoustic measurements showed no statistically significant changes.
- Without a control group, the study cannot establish that PRP caused the improvements.
Methodology
This single-center retrospective study included 36 patients with presbyphonia, with a mean age of 72.78 years, treated between October 2021 and April 2025. Patients received two to three office-based autologous PRP injections into the thyroarytenoid muscle; 35 completed the primary protocol. Before-and-after evaluations assessed patient-reported voice handicap, clinician-rated voice quality, sustained vocalization, acoustic measurements, and vocal cord vibration.
Study Limitations
This summary is based on the abstract only, not the full paper. The small, single-center retrospective study lacked a control group, limiting causal conclusions and generalizability. Although the authors describe treatment as safe and well tolerated, the abstract provides no detailed adverse event data, clear follow-up duration, or evidence of lasting benefit.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: